Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COM
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
29M
-
Shares change
-
-699K
-
Total reported value, excl. options
-
$537M
-
Value change
-
-$12.1M
-
Put/Call ratio
-
1.35
-
Number of buys
-
48
-
Number of sells
-
-58
-
Price
-
$18.51
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q1 2021
132 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q1 2021.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29M shares
.
Largest 10 shareholders include HILLHOUSE CAPITAL ADVISORS, LTD. (2.92M shares), VANGUARD GROUP INC (2.8M shares), BAKER BROS. ADVISORS LP (2.8M shares), PICTET ASSET MANAGEMENT LTD (2.49M shares), BlackRock Inc. (2.25M shares), STATE STREET CORP (1.41M shares), AMERIPRISE FINANCIAL INC (1.37M shares), Avidity Partners Management LP (1.33M shares), JANUS HENDERSON GROUP PLC (1.13M shares), and CITADEL ADVISORS LLC (1.02M shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.